The U.S. Supreme Court opens its term this week with a challenge that could have profound business implications for patent holders and those who pay them for licenses. Though the other patent case on the Court's docket, KSR International v. Teleflex -- the challenge to the Federal Circuit's obviousness standard -- is receiving great attention, MedImmune v. Genentech also has high stakes. Says one patent scholar, "in the economic scheme of things, this case is more important than KSR."
High Court Patent Case May Have Profound Business Impact
The National Law Journal
October 3, 2006
This article requires premium access
This article requires premium access to Law.com. Please sign in or subscribe to read the full text.